Clinical Trial Update: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) [Phase 3]

View source ↗

Summary

A Phase 3 trial MK-7339-012/KEYLYNK-012 evaluating pembrolizumab with concurrent chemoradiation followed by pembrolizumab with or without olaparib in stage III …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING